Integrated continuous manufacturing of therapeutic protein drug substances

Patent metadata

Field	Value
Publication number	US-10711034-B2
Application number	US-201715493523-A
Country	US
Kind code	B2
Filing date	Apr 21, 2017
Priority date	Mar 8, 2013
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

Provided herein are integrated continuous biomanufacturing processes for producing a therapeutic protein drug substance. Also provided are systems that are capable of continuously producing a therapeutic protein drug substance.

First claim

What is claimed is:

1. A process for manufacturing a drug substance comprising a recombinant α-galactosidase-A, the process comprising:
(a) culturing cells in a perfusion bioreactor comprising a liquid culture medium under conditions that allow the cells to secrete the recombinant α-galactosidase-A into the medium, wherein at least 90% cell-free volumes of the medium are continuously or periodically removed from the perfusion bioreactor and fed into a periodic counter current chromatography system (PCCS);
(b) capturing the recombinant α-galactosidase-A from the medium using a hydrophobic interaction and anion exchange resin in the PCCS; and
(c) further purifying and polishing the recombinant α-galactosidase-A by performing, sequentially, hydrophobic interaction chromatography, viral inactivation, cation exchange chromatography, and affinity chromatography, to yield the drug substance.

2. The process of claim 1 , wherein the use of the PCCS includes column switching.

3. The process of claim 1 , wherein the use of the PCCS utilizes at least two chromatography columns.

4. The process of claim 1 , wherein step (c) includes the use of an additional PCCS.

5. The process of claim 4 , wherein the additional PCCS is used to perform at least one of the hydrophobic interaction chromatography, viral inactivation, cation exchange chromatography, and affinity chromatography in step (c).

6. The process of claim 5 , wherein the additional PCCS is used to perform at least two of the hydrophobic interaction chromatography, cation exchange chromatography, and affinity chromatography in step (c), and the additional PCCS includes the use of two chromatography resins that have different chemical structures.

7. The process of claim 4 , wherein the use of the additional PCCS includes column switching.

8. The process of claim 4 , wherein the use of the additional PCCS utilizes at least two chromatography columns.

9. The process of claim 1 , wherein the cell-free volumes of the medium are directly fed from the bioreactor into the PCCS.

10. The process of claim 1 , wherein the cell-free volumes of the medium flowed from the bioreactor are held in a break tank, before being fed into the PCCS.

11. The process of claim 1 , wherein the cell grows in suspension.

12. The process of claim 11 , wherein the cell is a mammalian cell.

13. The process of claim 12 , wherein the mammalian cell is a Chinese hamster ovary (CHO) cell.

14. The process of claim 1 , wherein the process is integrated and runs continuously from the step (a) through step (c).

15. The process of claim 14 , further comprising:
(d) filtering the drug substance.

16. The process of claim 15 , further comprising:
(e) formulating the drug substance into a pharmaceutical composition.

17. The process of claim 1 , wherein the recombinant α-galactosidase-A is agalsidase beta.

Assignees

• Genzyme Corp

Inventors

• Konstantinov Konstantin
• Godawat Rahul
• Warikoo Veena
• Jain Sujit

Classifications

• C12M47/12

  Purification (C12M47/04 takes precedence) · CPC title

• C07K1/22 Primary

  Affinity chromatography or related techniques based upon selective absorption processes · CPC title

• C12N9/24

  acting on glycosyl compounds (3.2) · CPC title

• C07K1/16

  by chromatography · CPC title

• C12Q1/6806

  Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title